Moreau, M.; Carmona-Iragui, M.; Altuna, M.; Dalzon, L.; Barroeta, I.; Vilaire, M.; Durand, S.; Fortea, J.; Rebillat, A.-S.; Janel, N.
DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients. Biomedicines 2022, 10, 1380.
https://doi.org/10.3390/biomedicines10061380
AMA Style
Moreau M, Carmona-Iragui M, Altuna M, Dalzon L, Barroeta I, Vilaire M, Durand S, Fortea J, Rebillat A-S, Janel N.
DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients. Biomedicines. 2022; 10(6):1380.
https://doi.org/10.3390/biomedicines10061380
Chicago/Turabian Style
Moreau, Manon, Maria Carmona-Iragui, Miren Altuna, Lorraine Dalzon, Isabel Barroeta, Marie Vilaire, Sophie Durand, Juan Fortea, Anne-Sophie Rebillat, and Nathalie Janel.
2022. "DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients" Biomedicines 10, no. 6: 1380.
https://doi.org/10.3390/biomedicines10061380
APA Style
Moreau, M., Carmona-Iragui, M., Altuna, M., Dalzon, L., Barroeta, I., Vilaire, M., Durand, S., Fortea, J., Rebillat, A.-S., & Janel, N.
(2022). DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients. Biomedicines, 10(6), 1380.
https://doi.org/10.3390/biomedicines10061380
